Cargando…

Safety, Pharmacokinetics, and Immunogenicity of Obiltoxaximab After Intramuscular Administration to Healthy Humans

Inhalational anthrax is a highly lethal infection caused by Bacillus anthracis and a serious bioterrorism threat. Protective antigen (PA) is a critical component required for the virulence of Bacillus anthracis. Obiltoxaximab, a high‐affinity monoclonal antibody that neutralizes PA, is approved in t...

Descripción completa

Detalles Bibliográficos
Autores principales: Nagy, Christa F., Leach, Timothy S., King, Alex, Guttendorf, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6668011/
https://www.ncbi.nlm.nih.gov/pubmed/29125719
http://dx.doi.org/10.1002/cpdd.410
_version_ 1783440139991646208
author Nagy, Christa F.
Leach, Timothy S.
King, Alex
Guttendorf, Robert
author_facet Nagy, Christa F.
Leach, Timothy S.
King, Alex
Guttendorf, Robert
author_sort Nagy, Christa F.
collection PubMed
description Inhalational anthrax is a highly lethal infection caused by Bacillus anthracis and a serious bioterrorism threat. Protective antigen (PA) is a critical component required for the virulence of Bacillus anthracis. Obiltoxaximab, a high‐affinity monoclonal antibody that neutralizes PA, is approved in the United States for intravenous use for the treatment of inhalational anthrax in combination with appropriate antibacterial drugs and for prophylaxis of inhalational anthrax when alternative therapies are not available or appropriate. Here, we explored the safety, pharmacokinetics (PK), and immunogenicity of obiltoxaximab administered by intramuscular injection at doses of 4, 8, 16, 20, and 24 mg/kg in healthy humans. Systemic exposures were approximately dose proportional, maximum serum concentrations were observed after 6–9 days, and terminal half‐life ranged from 16 to 23 days. Average absolute intramuscular bioavailability was 64%. Obiltoxaximab was well tolerated, and local tolerability was acceptable up to 24 mg/kg intramuscularly, up to 6 injections per dose, and up to 5 mL per injection. No injection‐site abscesses or hypersensitivity reactions occurred; no subjects developed treatment‐emergent antitherapeutic antibodies over the study period of 71 days.
format Online
Article
Text
id pubmed-6668011
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-66680112019-08-06 Safety, Pharmacokinetics, and Immunogenicity of Obiltoxaximab After Intramuscular Administration to Healthy Humans Nagy, Christa F. Leach, Timothy S. King, Alex Guttendorf, Robert Clin Pharmacol Drug Dev Articles Inhalational anthrax is a highly lethal infection caused by Bacillus anthracis and a serious bioterrorism threat. Protective antigen (PA) is a critical component required for the virulence of Bacillus anthracis. Obiltoxaximab, a high‐affinity monoclonal antibody that neutralizes PA, is approved in the United States for intravenous use for the treatment of inhalational anthrax in combination with appropriate antibacterial drugs and for prophylaxis of inhalational anthrax when alternative therapies are not available or appropriate. Here, we explored the safety, pharmacokinetics (PK), and immunogenicity of obiltoxaximab administered by intramuscular injection at doses of 4, 8, 16, 20, and 24 mg/kg in healthy humans. Systemic exposures were approximately dose proportional, maximum serum concentrations were observed after 6–9 days, and terminal half‐life ranged from 16 to 23 days. Average absolute intramuscular bioavailability was 64%. Obiltoxaximab was well tolerated, and local tolerability was acceptable up to 24 mg/kg intramuscularly, up to 6 injections per dose, and up to 5 mL per injection. No injection‐site abscesses or hypersensitivity reactions occurred; no subjects developed treatment‐emergent antitherapeutic antibodies over the study period of 71 days. John Wiley and Sons Inc. 2017-11-10 2018-08 /pmc/articles/PMC6668011/ /pubmed/29125719 http://dx.doi.org/10.1002/cpdd.410 Text en © 2017 The Authors. Clinical Pharmacology in Drug Development Published by Wiley Periodicals, Inc. on behalf of The American College of Clinical Pharmacology This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Articles
Nagy, Christa F.
Leach, Timothy S.
King, Alex
Guttendorf, Robert
Safety, Pharmacokinetics, and Immunogenicity of Obiltoxaximab After Intramuscular Administration to Healthy Humans
title Safety, Pharmacokinetics, and Immunogenicity of Obiltoxaximab After Intramuscular Administration to Healthy Humans
title_full Safety, Pharmacokinetics, and Immunogenicity of Obiltoxaximab After Intramuscular Administration to Healthy Humans
title_fullStr Safety, Pharmacokinetics, and Immunogenicity of Obiltoxaximab After Intramuscular Administration to Healthy Humans
title_full_unstemmed Safety, Pharmacokinetics, and Immunogenicity of Obiltoxaximab After Intramuscular Administration to Healthy Humans
title_short Safety, Pharmacokinetics, and Immunogenicity of Obiltoxaximab After Intramuscular Administration to Healthy Humans
title_sort safety, pharmacokinetics, and immunogenicity of obiltoxaximab after intramuscular administration to healthy humans
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6668011/
https://www.ncbi.nlm.nih.gov/pubmed/29125719
http://dx.doi.org/10.1002/cpdd.410
work_keys_str_mv AT nagychristaf safetypharmacokineticsandimmunogenicityofobiltoxaximabafterintramuscularadministrationtohealthyhumans
AT leachtimothys safetypharmacokineticsandimmunogenicityofobiltoxaximabafterintramuscularadministrationtohealthyhumans
AT kingalex safetypharmacokineticsandimmunogenicityofobiltoxaximabafterintramuscularadministrationtohealthyhumans
AT guttendorfrobert safetypharmacokineticsandimmunogenicityofobiltoxaximabafterintramuscularadministrationtohealthyhumans